Possibilities of improving the parameters of hyperthermia in regional isolated limb perfusion using epidural bupivacaine and accurate temperature measurement of the three layers of limb tissue

The present study presents the author's modification of the method, which aims to create proper parameters of the treatment. The selected group consisted of 15 women and eight men, with a mean age of 57.2 years (range from 26 to 72 years). The patients were divided into two groups, depending on whether they were given epidural bupivacaine (group I – 13 patients treated between the years 2001 and 2004) or not [group II (control) – 10 patients treated earlier, between the years 1997 and 2000]. We observed a significant change in the temperature of thigh muscles (P=0.009) and shank muscles (P=0.006). In the control group II, there was a statistically significant difference (P=0.048) in the temperatures between the muscles and subcutaneous tissue on the one hand and the shank skin on the other. That difference was mean 0.67°C (from 0.4 to 0.9) during the perfusion after applying the cytostatic. The temperature of the skin was lower than the temperature of the deeper tissues of the shank and did not exceed 39.9°C. Such a difference in the temperatures was not observed in case of the group I patients who were given bupivacaine into the extrameningeal space before applying the cytostatic. The difference in the temperatures was on average 0.26°C and was not statistically significant (P=0.99), whereas the shank skin temperature was 40.0–40.6°C. The attained results imply that despite the noticeable improvement in the heating of the limb muscles after application of bupivacaine, the improvement in the heating of the skin and subcutaneous tissue is still not satisfactory, although the growing tendency implies such a possibility.

[1]  P. Schlag,et al.  Treatment of melanoma in-transit metastases confined to the limb , 1996, Acta Chirurgica Austriaca.

[2]  P. Schlag,et al.  Intracompartmental pressure during hyperthermic isolated limb perfusion for melanoma and sarcoma , 2006, Annals of Surgical Oncology.

[3]  R. Smalley,et al.  Hyperthermic perfusion with chemotherapy for melanoma of the extremities , 1989, World Journal of Surgery.

[4]  E. Krementz,et al.  The use of regional chemotherapy in the management of malignant melanoma , 1979, World Journal of Surgery.

[5]  S. Mocellin,et al.  Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases , 2004, Annals of Surgical Oncology.

[6]  A. Eggermont,et al.  Current uses of isolated limb perfusion in the clinic and a model system for new strategies. , 2003, The Lancet. Oncology.

[7]  L. Jost ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  D. Tyler,et al.  Long-Term Survival in 2,505 Patients With Melanoma With Regional Lymph Node Metastasis , 2002, Annals of surgery.

[9]  H. Hoekstra,et al.  Continuous Leakage Measurement During Hyperthermic Isolated Limb Perfusion , 2001, Annals of Surgical Oncology.

[10]  J. Thompson,et al.  Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies , 2001, British Journal of Cancer.

[11]  A. Eggermont,et al.  Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion , 2000, British Journal of Cancer.

[12]  A. Eggermont,et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. , 1999, Melanoma research.

[13]  A. Eggermont,et al.  Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Inbar,et al.  High dose tumor necrosis factor‐α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation , 1997, Cancer.

[15]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[16]  M. Papa,et al.  Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities. , 1996, American journal of surgery.

[17]  B. Vrouenraets,et al.  Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma , 1995, Melanoma research.

[18]  D. Fraker,et al.  Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. , 1995, The cancer journal from Scientific American.

[19]  R. Mirimanoff,et al.  Regional therapy of melanoma. , 1993, European journal of cancer.

[20]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Thomas,et al.  Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb , 1990, The British journal of surgery.

[22]  B. Kroon,et al.  Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  N. Cascinelli,et al.  Hyperthermic antiblastic perfusion in extracorporeal circulation: surgical technique and results in the treatment of extremities tumor , 1986 .

[24]  B. Mondovì,et al.  Selective Heat Sensitivity of Cancer Cells , 1977, Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer.

[25]  C. Heidelberger,et al.  Selective heat sensitivity of cancer cells. Biochemical and clinical studies , 1967 .

[26]  J. Stehlin,et al.  Regional chemotherapy for cancer: experiences with 116 perfusions. , 1960, Annals of surgery.

[27]  R. F. Ryan,et al.  Treatment of melanoma by isolation-perfusion technique. , 1959, Journal of the American Medical Association.